AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool.

Date publication

février 2023

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe

Tous les auteurs :
Piñero F, Costentin C, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas A, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Duque SH, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Carrilho F, Cherqui D, Burra P, Van Vlierberghe H, Lai Q, Silva M, Rubinstein F, Duvoux C, ,,,,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36691474

Résumé

Two recently developed composite models, the alpha-fetoprotein (AFP) score and Metroticket 2.0, could be used to select patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation (LT). The aim of this study was to compare the predictive performance of both models and to evaluate the net risk reclassification of post-LT recurrence between them using each model's original thresholds.

Mots clés

AFP, alpha-fetoprotein, HCC, hepatocellular carcinoma, HR, hazard ratio, LT, liver transplantation, NRI, net reclassification index, Prediction, SHR, sub-hazard ratio, reclassification, recurrence, transplantation

Référence

JHEP Rep. 2023 02;5(2):100644